N Van Zandwijk

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi request reprint Neoadjuvant strategies for non-small cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlann 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 34:S145-50. 2001
  2. ncbi request reprint New methods for early diagnosis of lung cancer
    Nico van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 38:S9-11. 2002
  3. ncbi request reprint Chemoprevention in lung carcinogenesis--an overview
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Plesmanlaan 121, 1066 CX, The Netherlands
    Eur J Cancer 41:1990-2002. 2005
  4. ncbi request reprint Chemoprevention of lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 34:S91-4. 2001
  5. ncbi request reprint [Therapeutic strategies in neoadjuvant therapy of non-small cell lung cancer: benefits of gemcitabine]
    N Van Zandwijk
    Département d Oncologie Thoracique, Netherlands Cancer Institute, 1066 CX Amsterdam, Pays Bas
    Anticancer Drugs 12:S15-9. 2001
  6. ncbi request reprint [Neoadjuvant strategies in the treatment of non-small cell lung cancer]
    N Van Zandwijk
    Institut Néerlandais du Cancer, Service d Oncologie Thoracique, Amsterdam, The Netherlands
    Anticancer Drugs 11:S17-22. 2000
  7. ncbi request reprint Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
    N Van Zandwijk
    Netherlands Cancer Institute and Free University, Amsterdam, The Netherlands
    J Clin Oncol 18:2658-64. 2000
  8. ncbi request reprint EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups
    N Van Zandwijk
    The Netherlands Cancer Institute, Amsterdam
    J Natl Cancer Inst 92:977-86. 2000
  9. ncbi request reprint The prognostic significance of a previous malignancy in operable non-small cell lung cancer
    M J Koppe
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 166, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 32:47-53. 2001
  10. doi request reprint Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis
    T W Geurts
    Department of ORL, Academic Medical Center, Amsterdam, Tumor Biology Section, Amsterdam, The Netherlands
    Clin Cancer Res 15:980-5. 2009

Detail Information

Publications56

  1. ncbi request reprint Neoadjuvant strategies for non-small cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlann 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 34:S145-50. 2001
    ..Given the systemic nature of lung cancer it is estimated that systemic therapy before local treatment will play an increasingly important role for patients with early-stage NSCLC...
  2. ncbi request reprint New methods for early diagnosis of lung cancer
    Nico van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 38:S9-11. 2002
    ....
  3. ncbi request reprint Chemoprevention in lung carcinogenesis--an overview
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Plesmanlaan 121, 1066 CX, The Netherlands
    Eur J Cancer 41:1990-2002. 2005
    ..This review, with a short update on pulmonary carcinogenesis, will summarize the available knowledge of chemoprevention trials and agents with a preventive potential in the 'lung field'...
  4. ncbi request reprint Chemoprevention of lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 34:S91-4. 2001
    ..This review summarizes the outcomes of recent clinical chemoprevention trials and reveals that the chemoprevention approach in lung cancer is still experimental...
  5. ncbi request reprint [Therapeutic strategies in neoadjuvant therapy of non-small cell lung cancer: benefits of gemcitabine]
    N Van Zandwijk
    Département d Oncologie Thoracique, Netherlands Cancer Institute, 1066 CX Amsterdam, Pays Bas
    Anticancer Drugs 12:S15-9. 2001
    ..Major studies are ongoing, one of which compares GC + surgery versus surgery alone (stages IB-IIIA); the other regimen aims to evaluate GC versus paclitaxel/carboplatin as well as two induction strategies...
  6. ncbi request reprint [Neoadjuvant strategies in the treatment of non-small cell lung cancer]
    N Van Zandwijk
    Institut Néerlandais du Cancer, Service d Oncologie Thoracique, Amsterdam, The Netherlands
    Anticancer Drugs 11:S17-22. 2000
    ....
  7. ncbi request reprint Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
    N Van Zandwijk
    Netherlands Cancer Institute and Free University, Amsterdam, The Netherlands
    J Clin Oncol 18:2658-64. 2000
    ....
  8. ncbi request reprint EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups
    N Van Zandwijk
    The Netherlands Cancer Institute, Amsterdam
    J Natl Cancer Inst 92:977-86. 2000
    ....
  9. ncbi request reprint The prognostic significance of a previous malignancy in operable non-small cell lung cancer
    M J Koppe
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 166, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 32:47-53. 2001
    ..NSCLC diagnosed during the follow-up of a previous malignancy, and deemed operable, therefore, warrants the same diagnostic and therapeutic approach as NSCLC as first malignancy...
  10. doi request reprint Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis
    T W Geurts
    Department of ORL, Academic Medical Center, Amsterdam, Tumor Biology Section, Amsterdam, The Netherlands
    Clin Cancer Res 15:980-5. 2009
    ..In this study, we use TP53 mutation analysis for validation of an allelic loss marker panel and a decision algorithm for distinguishing between DM and SPT...
  11. ncbi request reprint EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 18:99-103. 2007
    ..Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs...
  12. ncbi request reprint The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
    C J Hoekstra
    Clinical PET Centre, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    Lung Cancer 39:151-7. 2003
    ..These results show that using the conventional staging algorithm a substantial group of patients was understaged. FDG PET improves the selection of patients suitable for CMT...
  13. ncbi request reprint Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results
    H Schouwink
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Chest 120:1167-74. 2001
    ..The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use. Stricter patient selection and improvements of the IPDT technique may reduce the toxicity...
  14. ncbi request reprint Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
    A Haringhuizen
    Departments of Thoracic Oncology and Biometrics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Ann Oncol 15:786-92. 2004
    ..We describe 16 months' single-institution experience with gefitinib ("Iressa", ZD1839) used as "ultimum refugium" for pretreated non-small-cell lung cancer (NSCLC) patients...
  15. ncbi request reprint Chemoprevention of lung cancer: from concept to reality
    N Van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Rocz Akad Med Bialymst 48:5-10. 2003
    ....
  16. pmc Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies
    P Baas
    The Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam
    Br J Cancer 76:819-26. 1997
    ..This combination of light delivery and dosimetry is well suited for adjuvant treatment with PDT in malignant pleural tumours...
  17. ncbi request reprint Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients
    I Kappers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 59:385-90. 2008
    ..In this subgroup, concurrent chemoradiotherapy followed by surgery was associated with excellent local control and acceptable survival...
  18. pmc Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
    J H M Schellens
    The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 88:814-21. 2003
    ..Randomised studies are needed to determine whether the adaptive dosing strategy results in better efficacy than standard dosing...
  19. ncbi request reprint Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
    G Giaccone
    Division of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Clin Oncol 16:2133-41. 1998
    ..To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC)...
  20. pmc Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study
    P Baas
    Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Cancer 73:945-51. 1996
    ..3) Restoration of skin after PDT in previously treated tumour areas (chemotherapy, radiation therapy and surgery) is very low...
  21. ncbi request reprint The psychological impact of annual chest X-ray follow-up in head and neck cancer
    T W Geurts
    Department of Head and Neck Oncology and Surgery, The Nethelands Cance Institute Antoine van Leuwenhoek Hospital, Amsterdam, The Netherlands
    Acta Otolaryngol 126:1315-20. 2006
    ..A majority of patients regard the annual chest X-ray as a reassurance. Given these results a more intensive screening program seems psychologically justifiable for this group...
  22. pmc Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
    N Van Zandwijk
    Department of Thoracic Oncology and Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Br J Cancer 89:S9-14. 2003
    ..Overall, these tolerability data demonstrate that gefitinib has a relatively benign side-effect profile and is a well-tolerated treatment option for patients with previously treated NCSLC, who currently have few alternatives...
  23. ncbi request reprint Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma
    R E Kibbelaar
    Department of Pathology, The Netherlands Cancer Institute, Amsterdam
    Eur J Cancer 27:431-5. 1991
    ..Non-small cell lung carcinomas positive for MAb 123C3 showed post-operative overall and disease-free survival times significantly shorter than 123C3-negative non-small cell carcinomas...
  24. ncbi request reprint Radiation pneumonitis imaged with indium-111-pentetreotide
    R A Valdes Olmos
    Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Nucl Med 37:584-8. 1996
    ..Early recognition of radiation pneumonitis enables adequate treatment with a reasonable chance to prevent late sequelae. The feasibility of 111In-pentetreotide in detecting this condition was explored in this study...
  25. ncbi request reprint [Bronchoscopy: new diagnostic and therapeutic technology, new indications]
    J A Burgers
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Thoracale Oncologie, Plesmanlaan 121, 1066 CX Amsterdam
    Ned Tijdschr Geneeskd 148:1280-5. 2004
    ..Electrocauterization and laser dissection are regularly used to remove intrabronchial tumour depositions. Airway stenting is indicated if there are stenoses caused by compression from abnormalities located externally to the airways...
  26. ncbi request reprint Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study
    S Rodenhuis
    Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 15:285-91. 1997
    ..Mutational activation of K-ras is a strong adverse prognostic factor in stage I or II lung cancer and laboratory studies have suggested that ras mutations lead to resistance against ionizing radiation and chemotherapy...
  27. ncbi request reprint The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)
    P Baas
    The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Eur J Cancer 39:353-7. 2003
    ..We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted...
  28. ncbi request reprint Lung volume calculations from 81Krm SPECT for the quantification of regional ventilation
    A Zwijnenburg
    Department of Nuclear Medicine, Netherlands Cancer Institute, Antoni van Leeuwenhoekhuis, Amsterdam
    Clin Phys Physiol Meas 9:147-54. 1988
    ..It was concluded that the relative volume distribution, calculated from SPECT, can be used for the quantification of ventilation from 81Krm SPECT steady-state count distributions...
  29. pmc Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation
    H B Kwa
    Department of Tumour Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Br J Cancer 73:439-46. 1996
    ..In conclusion, accumulation and retention of radioactivity in the tumour tissue, due to internalisation of radiolabelled MAbs, may improve the results immunoscintigraphy...
  30. ncbi request reprint Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer
    Corneline J Hoekstra
    Department of Nuclear Medicine, Vrije University Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 23:8362-70. 2005
    ....
  31. ncbi request reprint Relationship between cisplatin administration and the development of ototoxicity
    Jeany M Rademaker-Lakhai
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital and Department of Audiology, Academic Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 24:918-24. 2006
    ..To determine the auditory toxicity associated with dose- and schedule- intensive cisplatin/gemcitabine chemotherapy in non-small-cell lung carcinoma patients...
  32. ncbi request reprint Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion
    Marina S Kartachova
    Department of Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:893-9. 2006
    ..The purpose of this study was to map treatment-induced (99m)Tc-Hynic-rh-annexin V uptake in normal tissues using co-registration of SPECT and CT...
  33. ncbi request reprint Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy
    Gijsbert W P M Kramer
    Radiotherapeutic Institute ARTI, Wagnerlaan 47, 6815 Arnhem, The Netherlands
    Eur J Cancer 42:1391-8. 2006
    ..Protocol amendment resulted in an improvement of the quality and the compliance of most observed parameters, at the cost of some increase in overall treatment time. The latter reflects logistical problems rather than poor compliance...
  34. ncbi request reprint Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
    Jose Belderbos
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Eur J Cancer 43:114-21. 2007
    ..A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients...
  35. doi request reprint Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer
    Ingrid Kappers
    Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 26:4205-7. 2008
  36. ncbi request reprint Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer
    Marina Kartachova
    Department of Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 25:2534-9. 2007
    ..The purpose of this study was to evaluate if sequential 99mTc Hynic-rh- annexin V scintigraphy (TAS) can predict outcome in patients with advanced lung cancer, shortly after the start of platinum-based chemotherapy...
  37. ncbi request reprint The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium
    Remco M van den Berg
    Department of Pulmonology, VU Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Am J Respir Crit Care Med 175:1061-5. 2007
    ..Bronchial epithelium exposed to cigarette smoke undergoes a series of histologic changes that may ultimately lead to invasive cancer. Inhaled corticosteroids reduce the number of lung tumors developing in rats exposed to cigarette smoke...
  38. ncbi request reprint Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer
    Jan P van Meerbeeck
    Department of Respiratory Medicine, 7K12IE, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium
    J Natl Cancer Inst 99:442-50. 2007
    ..We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy...
  39. ncbi request reprint Chemoprevention of lung cancer: soon daily practice?
    Nico van Zandwijk
    Head Dept Thoracic Oncology, Netherlands Cancer Institute, Amsterdam
    Expert Rev Anticancer Ther 3:91-8. 2003
    ..After more than 20 years of worldwide research, the prospects for effective lung cancer treatment are better than ever...
  40. ncbi request reprint Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers
    Frederik Jan van Schooten
    Department of Health Risk Analysis and Toxicology, Maastricht University, The Netherlands
    Cancer Epidemiol Biomarkers Prev 11:167-75. 2002
    ..1) but not on BAL fluid antioxidant scavenging capacity. We conclude that NAC has the potential to impact upon tobacco smoke carcinogenicity in humans because it can modulate certain cancer-associated biomarkers in specific organs...
  41. ncbi request reprint Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Suppl Tumori 1:S37-8. 2002
  42. ncbi request reprint The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma
    J Hugo Schouwink
    Department of Thoracic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Ann Thorac Surg 75:1715-8; discussion 1718-9. 2003
    ..In this study cervical mediastinoscopy (CM) is compared with computer tomography (CT) scanning for its diagnostic accuracy in assessing mediastinal lymph nodes during preoperative workup...
  43. ncbi request reprint Chemoprevention of lung cancer: current status and future prospects
    Nico van Zandwijk
    Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Lung Cancer 42:S71-9. 2003
    ..This article reviews the lung cancer chemoprevention efforts of the last two decades and also gives prospects for the next coming years...
  44. ncbi request reprint Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer
    Pieter E Postmus
    Department of Pulmonary Diseases, Vrije Universiteit Medical Cetner, Amsterdam, Netherlands
    Lung Cancer 42:S3-6. 2003
  45. ncbi request reprint Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 10:2237-44. 2004
    ..The paclitaxel dose of a subsequent course was increased to the lowest dose for which the predicted time period during which the paclitaxel plasma concentration exceeds 0.1 micromol/liter was >15 h...
  46. ncbi request reprint In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response
    Marina Kartachova
    Department of Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Radiother Oncol 72:333-9. 2004
    ..99m)Tc-Hynic-rh-Annexin V scintigraphy (TAVS) enables non-invasive in vivo imaging of treatment-induced apoptosis. We identified the visual patterns of (99m)Tc-Hynic-rh-Annexin V tumour uptake and related these to treatment response...
  47. ncbi request reprint Thalidomide in patients with malignant pleural mesothelioma
    Paul Baas
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Lung Cancer 48:291-6. 2005
    ..The purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM)...
  48. ncbi request reprint Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma
    Eelco de Bree
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Chest 121:480-7. 2002
    ..We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity...
  49. ncbi request reprint Chemoprevention strategies for non-small cell lung cancer
    Nico van Zandwijk
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Curr Opin Oncol 14:185-90. 2002
    ..However, recent developments in molecular biology and increased insight in lung carcinogenesis have led to the potential of more specifically targeted intervention and optimism for new, successful chemopreventive approaches...
  50. pmc Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    PLoS ONE 3:e0001722. 2008
    ..Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease...
  51. ncbi request reprint CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone
    Remco M van den Berg
    Department of Pulmonology, VU University Medical Center, Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Lung Cancer 60:57-61. 2008
    ..We performed a secondary analysis of CT data of subjects at risk of lung cancer enrolled in a chemoprevention trial of fluticasone...
  52. ncbi request reprint Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers
    Claudia A L Ruivenkamp
    Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Nat Genet 31:295-300. 2002
    ..Our data suggest that PTPRJ is relevant to the development of several different human cancers...
  53. ncbi request reprint Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Jeany M Rademaker-Lakhai
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Anticancer Drugs 16:1029-36. 2005
    ..We conclude that the combination of cisplatin at a dose intensity of 51 mg/m/week followed by gemcitabine (1500 mg/m) on the same day is clinically feasible in NSCLC patients when given as a 2-weekly cycle...
  54. ncbi request reprint Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Mirjam Crul
    Netherlands Cancer Institute, Departments of Medical Oncology, The Netherlands
    Clin Cancer Res 9:3526-33. 2003
    ..To establish the maximum dose intensity of cisplatin plus gemcitabine on a weekly or two-weekly schedule in patients with advanced non-small cell lung cancer (NSCLC)...
  55. ncbi request reprint Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?
    Tom W Geurts
    Department of ORL, Academic Medical Center, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 11:6608-14. 2005
    ..To distinguish a metastasis from a second primary tumor in patients with a history of head and neck squamous cell carcinoma and subsequent pulmonary squamous cell carcinoma...
  56. ncbi request reprint Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics
    Nico van Zandwijk
    Lung Cancer 51:137-8. 2006